CompletedNCT01172652
Ziprasidone for Anxiety Symptoms in People Living With Bipolarity
About this title
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
Read the official source — NCT01172652Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Palo Alto and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 49
- Sponsor
- VA Palo Alto Health Care System
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01172652
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Palo Alto · Tampa · Mason
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is VA Palo Alto Health Care System.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
